BNP Paribas Financial Markets’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $15.9M | Buy |
|
|||||
|
2025
Q2 | $13.1M | Buy |
|
|||||
|
2025
Q1 | $942K | Sell |
|
|||||
|
2024
Q4 | $1.48M | Sell |
|
|||||
|
2024
Q3 | $3.78M | Buy |
|
|||||
|
2024
Q2 | $537K | Sell |
|
|||||
|
2024
Q1 | $852K | Sell |
|
|||||
|
2023
Q4 | $4.73M | Buy |
|
|||||
|
2023
Q3 | $3.84M | Buy |
|
|||||
|
2023
Q2 | $1.52M | Sell |
|
|||||
|
2023
Q1 | $2.84M | Buy |
|
|||||
|
2022
Q4 | $1.8M | Sell |
|
|||||
|
2022
Q3 | $3.02M | Buy |
|
|||||
|
2022
Q2 | $430K | Buy |
|
|||||
|
2022
Q1 | $420K | Sell |
|
|||||
|
2021
Q4 | $912K | Buy |
|
|||||
|
2021
Q3 | $631K | Buy |
|
|||||
|
2021
Q2 | $265K | Sell |
|
|||||
|
2021
Q1 | $311K | Buy |
|
|||||
|
2020
Q4 | $140K | Sell |
|
|||||
|
2020
Q3 | $142K | Buy |
|
|||||
|
2020
Q2 | $170K | Sell |
|
|||||
|
2020
Q1 | $141K | Buy |
|
|||||
|
2019
Q4 | $59.3K | Sell |
|
|||||
|
2019
Q3 | $50K | Buy |
|
|||||
|
2019
Q2 | $46.5K | Sell |
|
|||||
|
2019
Q1 | $185K | Buy |
|
|||||
|
2018
Q4 | $299 | Sell |
|
|||||
|
2018
Q3 | $24.9K | Hold |
|
|||||
|
2018
Q2 | $18.7K | Sell |
|
|||||
|
2018
Q1 | $96.9K | Sell |
|
|||||
|
2017
Q4 | $100K | Buy |
|
|||||
|
2017
Q3 | $43.3K | Sell |
|
|||||
|
2017
Q2 | $49.2K | Buy |
|
|||||
|
2017
Q1 | $3.09K | Sell |
|
|||||
|
2016
Q4 | $26K | Sell |
|
|||||
|
2016
Q3 | $22.5K | Buy |
|
|||||
|
2016
Q2 | $8.27K | Buy |
|
|||||
|
2016
Q1 | – | Sell |
|
|||||
|
2015
Q4 | $153K | Sell |
|
|||||
|
2015
Q3 | $171K | Buy |
|
|||||
|
2015
Q2 | $90.1K | Buy |
|
|||||
|
2015
Q1 | $14.9K | Buy |
|
|||||
|
2014
Q4 | – | Sell |
|
|||||
|
2014
Q3 | $41K | Buy |
|